Oncolytics Biotech
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4350 Executive Dr Ste 325, San Diego, Ca...Phone Number
(403) 670-7377Website
www.oncolyticsbiotech.comRevenue
$26.1 MillionStock Symbol
ONCYIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
3
1
1
1
1
About Oncolytics Biotech
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. The company was founded in 1998 and is based out of Alberta, Canada.Explore more
Oncolytics Biotech Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Oncolytics Biotech your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Oncolytics Biotech recently announced quarterly report
Check if Oncolytics Biotech has recently received funding, and reach out quickly before it becomes old news!
Check out if Oncolytics Biotech is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Oncolytics Biotech
Click to see if Oncolytics Biotech had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Oncolytics Biotech has new funding data
Product Launch: Get notified when Oncolytics Biotech launches new products
Website visits: Recent activity has been detected on your website
Oncolytics Biotech, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Oncolytics Biotech
Compare insights from companies similar to Oncolytics Biotech, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Oncolytics Biotech is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Oncolytics Biotech is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Oncolytics Biotech.
Oncolytics Biotech financials insights
Gather financial insights about Oncolytics Biotech, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$15M
Oncolytics Biotech Tech Stack
A closer look at the technologies used by Oncolytics Biotech
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Oncolytics Biotech announced a strategic focus on accelerating its immunotherapy candidate Pelareorep into a registration-enabled study for first-line pancreatic cancer, aiming to unlock its full commercial potential and create conditions for a transformational transaction.
Research & Development, Pharmaceuticals, Corporate Strategy
Project
Oncolytics Biotech announced a new strategic focus on becoming the only platform immunotherapy in gastrointestinal cancer. The company expects to achieve key milestones in 2025, including patent extension, regulatory clarity on a registration-enabled study, and data maturation in anal carcinoma and first-line pancreatic cancer.
Research & Development, Pharmaceuticals, Corporate Strategy
Event
Oncolytics Biotech announced its annual meeting agenda, which includes presenting financial statements for fiscal 2024, setting the number of directors, electing directors, and appointing auditors for the ensuing year.
Accounting, Financial Reporting, Corporate Strategy, Finance, Governance
Earnings
Earnings, Accounting, Financial Reporting, Finance
Oncolytics Biotech News & Media
Oncolytics Biotech® Announces Appointment of Steve Glover to Board of Directors and Promotion of John McAdory to Chief Operating Officer
Oncolytics Biotech announced the appointment of Steve Glover to its Board of Directors and the promotion of John McAdory to Chief Operating Officer.Oncolytics Biotech® Announces Positive Initial Preclinical Findings Supporting Further Evaluation of Pelareorep in Combination with RAS-Targeted Approaches
Oncolytics announced data demonstrating evidence of greater anti-tumor activity with pelareorep in combination with RAS inhibitor modalities.Oncolytics Biotech® to Present Data at ASCO 2026 Reinforcing Pelareorep’s Potential Across Gastrointestinal Tumors
Translational data demonstrate induction of both innate and adaptive antiviral and anti-tumor specific immune responses capable of controlling tumor growthOncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
Oncolytics announced new data in metastatic colorectal cancer, demonstrating 3-4x improvement in duration response vs. historical 4-6 month benchmark.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Oncolytics Biotech
Sign Up For FreeTo access detailed company insights
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combina... Read More
